Activities Report and Appendix 4C for March 2022 Quarter

Melbourne (Australia) – 22 April 2022. Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2022.

Telix is pleased to provide its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2022.

Dr. Christian Behrenbruch, Managing Director and Telix Group CEO said “This has been a pivotal quarter for Telix, as we delivered on several major objectives including the Company transformational event of launching of our first commercial product and completion of target enrolment for a Phase III clinical trial.

We are strongly encouraged by the level of anticipation and early demand for Illuccix^®, both in the independent imaging centre and hospital-based segments of the U.S. market, driven by clear inclusion in clinical practice guidelines and, more recently, indicated as a patient selection tool for next-generation prostate cancer therapy. Telix is uniquely positioned to deliver this product on-demand, coast-to-coast across the U.S. With the recent FDA approval of PSMA-targeted radiotherapy – and the importance of ⁶⁸Ga-PSMA-11 for patient selection – it is an exciting time for molecular imaging in Genitourinary, or ‘GU’ Oncology.

“The recent financing activity – including the $175.0 million placement and $18.2 million project financing package for the buildout of the Company’s European manufacturing site will support Telix’s growth trajectory as a market leader in the field of radiopharmaceuticals. From a product development and manufacturing perspective, these financial resources enable will enable Telix to advance an important pipeline of products that address major unmet medical need.”

To view the Appendix 4C and Activities Report please click here. 

To return to Telix’s homepage please click  here.